Course Description
Cannabis laws continue to change, and more states have laws either decriminalizing or legalizing marijuana and cannabis products. Increases in cannabis-related hospitalizations have been noted with presentations ranging from edible overdose/intoxication to cannabis hyperemesis syndrome. Chronic daily users of marijuana may be admitted to the hospital and be at risk for cannabis withdrawal. In psychiatry, we need to know how cannabis use disorder may impact other substance use disorders or psychiatric illness. Given the hot topic of cannabis and the ever-changing laws, it is important for psychiatric pharmacists to be proficient in caring for those with cannabis use disorders and managing the potential sequelae of chronic cannabis use.
Learning Objectives
- Illustrate the risk of marijuana use, change in potency, and routes of administration on developing of Cannabis use disorder and other psychiatric disorders.
- Evaluate the evidence for managing Cannabis use disorder, Cannabis withdrawal, and cannabinoid hyperemesis syndrome.
- Construct management plans for cannabis use disorder, cannabinoid hyperemesis syndrome, and Cannabis withdrawal.
Target Audience
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric patients, we invite you to participate in this online course.
Faculty
View biographical information
Kari Franson, PharmD, PhD, BCPP
Associate Dean of Academic & Student Affairs
University of Southern California School of Pharmacy
Los Angeles, CA
Kari L. Franson, PharmD, PhD, BCPP is Professor of Clinical Pharmacy and Associate Dean for Academic and Student Affairs at the University of Southern California School of Pharmacy. She received her doctor of pharmacy from the University of California, San Francisco, trained at the University of Illinois, Chicago Hospital and Clinics as a resident in adult internal medicine and a fellow in clinical research/drug development, and received her PhD in medical education from Leiden University, the Netherlands.
Dr. Franson is an educator with more than 25 years of experience. She is an international leader in interprofessional practice, education and advocacy and workforce development to address health disparities in both the U.S. and abroad. Dr. Franson has experience in campus and distance-based curriculum development and assessment, technology-enhanced assessment/learning, experiential education, and continuing professional education and development.
Dr. Franson has trained as a U.S. Board-Certified Psychiatric Pharmacist and Dutch-Certified Clinical Pharmacologist. She worked with geriatric psychiatric patients for 10 years and has performed a variety of clinical studies spanning those in early-phase clinical pharmacology to post-marketing clinical efficacy studies. She is interested in cannabinoid clinical pharmacologic effects and cannabis user safety. She has guided national and international professional, legislative, media and commercial groups on the wise study and use of cannabis.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Date: 10/06/2022
ACPE Contact Hours: 1.25
ACPE Number: 0284-0000-22-070-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2022 Planning Committee
|
Ericka Crouse, PharmD, BCPP, BCGP, FASHP, FASCP Associate Professor VCU School of Pharmacy Richmond, VA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: ASHP - PAM Behavioral Health Committee (volunteer), Editorial Board - The Medical Letter (paid), American Society of Consultant Pharmacists - speak at meetings/webinars on GeroPsych topics (paid), Wolters-Kluwer, paid consultant |
|
Cassandra Davis, PharmD, BCPP, BCPS Mental Health Clinical Pharmacy Specialist Orlando VA Medical Center Orlando, FL No Relevant Financial Relationships to Disclose |
 Megan J. Ehret, PharmD, BCPP, MSBCPP Program Director Professor University of Maryland Baltimore, MD External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Psych U Section Advisor, Lexi-Comp Consultant/Reviewer, SMI Adviser; Pharmacist Consultant Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH |
 Sarah Melton, PharmD, BCPP, BCACP, FASCPChair Professor of Pharmacy Practice Gatton College of Pharmacy Johnson City, TN Non-Financial Interests: One Care of Southwest Virginia, Virginia Board of Pharmacy, Virginia Opioid Abatement Authority, Overmountain Recovery, Virginia Department of Health Professions Board, Virginia Medicaid Pharmacy and Therapeutics Committee |
|
Troy Moore, PharmD, MS, BCPP |
|
Erika Titus-Lay, PharmD, BCPP, BCPS Assistant Professor California Northstate University College of Pharmacy Elk Grove, CA Educational Grants, Research Grants or Contracts: Sponsor, ASHP Pharmacy Leadership Scholars Research Grant |
2022 Reviewers
|
Audrey Abelleira, PharmD, BCPP, BCPS |
|
David Dadiomov, PharmD, BCPP |
|
James J. Gasper, PharmD, BCPP |
|
Cindy A. Gutierrez, PharmD, MS, BCPP |
|
Dara L. Johnson, PharmD, BCPP, BCACP |
|
Benjamin Miskle, PharmD |
|
Marnie Noel, PharmD, BCPP |
All relevant relationships have been mitigated.
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Medical Cannabis including tetrahydrocannabinol (THC) and cannabidiol (CBD)
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.